MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding (i) 5.875% Senior Secured Notes due 2027 (the “2027 Notes”) and (ii) 5.875% Senior Notes due 2026 (the “2026 Notes” and, collectively with the 2027 Notes, the “Notes” and each a “Series” of Notes). The terms and conditions of the Tender Offer are described in an Off ...

Core Viewpoint - Norwegian Cruise Line Holdings Ltd. has initiated a registered direct offering of ordinary shares to certain holders of its subsidiary's exchangeable senior notes, aiming to facilitate repurchases of these notes [1][2]. Group 1: Equity Offering Details - The company is conducting an Equity Offering to specific holders of NCL Corporation Ltd.'s 1.125% and 2.50% Exchangeable Senior Notes due 2027 [1]. - The net proceeds from the Equity Offering will be used alongside proceeds from a separate private offering of exchangeable senior notes due 2030 to repurchase a portion of the 2027 Exchangeable Notes [2]. - The completion of the Repurchases is contingent upon the successful execution of both the Equity Offering and the Exchangeable Notes Offering [2]. Group 2: Placement and Regulatory Information - J.P. Morgan Securities LLC is serving as the exclusive placement agent for the Equity Offering [3]. - The offering is being conducted under an automatic shelf registration statement filed with the U.S. SEC on November 8, 2023, and will be accompanied by a prospectus supplement [3].

MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (“NCLH”), announced today that it is proposing to sell $1,025.0 million aggregate principal amount of its senior notes due 2031 (the “2031 Unsecured Notes”) and $1,025.0 million aggregate principal amount of its senior notes due 2033 (the “2033 Unsecured Notes” and, collectively with the 2031 Unsecured Notes, the “Unsecured Notes”) in a private offering (the “Unsecured No ...

Core Viewpoint - A.P. Møller - Mærsk A/S has increased its treasury shares to 5% of the share capital as part of an ongoing share buy-back program aimed at adjusting the company's capital structure through the eventual cancellation of repurchased shares [2][3]. Group 1 - As of 5 September 2025, A.P. Møller - Mærsk A/S owned 5.03% of its shares, comprising 104,279 A-shares and 691,647 B-shares [2]. - The share buy-back program is intended to adjust the capital structure of the company [3].

Revenue grew 26% year-over-year, and 49% in constant currency in H1 2025 over H1 2024 Achieved Net Income of $0.43 million in H1 2025 The share of dollar-pegged revenue in our portfolio increased from 18% in H1 2024 to 34% in H1 2025, with recurring revenue reaching 85% of total revenue and Net Dollar Retention of 118% DUBAI, United Arab Emirates, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Swvl Holdings Corp (“Swvl” or the “Company”) (Nasdaq: SWVL), a global provider of transformative tech-enabled mass transit sol ...

LONDON and ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that U.K.-based customs consultancy Customs Assured is streamlining and automating large portions of the customs documentation process for its clients by using Descartes e-Customs™. Enhanced by artificial intelligence (AI) from AiDock, the combined solution reduces the time spent on repetitive manual tasks associated with c ...

LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Playboy, Inc. (Nasdaq: PLBY) (the “Company” or “Playboy”), one of the most recognizable and iconic brands in the world, announced today that it has prevailed in its arbitration against its terminated licensee, New Handong Investment (Guangdong) Co., Ltd. (“New Handong”), and has been awarded damages of approximately $81 million, including accrued interest. As previously described in further detail in the Company’s periodic reports, including in the Company’s Q ...

Core Insights - Regeneron Pharmaceuticals has announced positive results from Phase 3 trials of its investigational allergen-blocking antibodies for treating moderate-to-severe cat and birch allergies, showing significant reduction in allergy symptoms compared to placebo [1][2][4][12] Cat Allergy Program - The cat allergy program involved two monoclonal antibodies, REGN1908 and REGN1909, targeting FelD1, the dominant cat allergen, which affects over 20 million patients in the U.S. [3][4] - In the Phase 3 trial, participants receiving the antibody combination showed a 52% reduction in ocular itch, 39% in conjunctival redness, and 44% in skin prick reactivity, all with high statistical significance [4][12] - The treatment was well-tolerated, with no serious adverse events reported, and further Phase 3 development is planned for the first half of 2026 [4][12] Birch Allergy Program - The birch allergy program utilized REGN5713 and REGN5715 monoclonal antibodies targeting BetV1, affecting over 10 million people in the U.S. [5][6] - In the Phase 3 trial, participants receiving the BetV1-blocking antibodies experienced a 51% reduction in ocular itch, 46% in conjunctival redness, and 44% in skin prick reactivity, all statistically significant [12] - Similar to the cat allergy trials, the birch allergy treatment was well-tolerated, with no serious adverse events, and additional Phase 3 development is expected to begin by the end of the year [12] Broader Allergy Pipeline - Regeneron is also conducting a proof-of-concept trial for severe food allergies, which involves a novel approach of ablating IgE-producing cells followed by treatment with Dupixent [7] - Initial results from the food allergy trial have been encouraging, with completion of enrollment expected by the end of the year [7] Technology and Innovation - Regeneron's VelocImmune technology, which produces fully human antibodies, has been instrumental in developing these investigational treatments [9][10] - The company has a strong track record of translating scientific discoveries into approved therapies, with a focus on serious diseases [10][11]

Core Viewpoint - A permanent exhibition honoring the Flying Tigers, American volunteer pilots who fought alongside Chinese forces during World War II, has opened in Liuzhou, Guangxi Zhuang Autonomous Region, China [1]. Group 1: Exhibition Details - The exhibition is housed in the Liuzhou Military Museum and features over 1,000 artifacts, including flight suits, arm patches, letters, and diaries, many donated by individuals from both China and the United States [3]. - The exhibition will be open to the public free of charge and consists of five themed sections that present the stories of American pilots fighting alongside Chinese soldiers and civilians during the war [7]. Group 2: Historical Context - Liuzhou served as a key transportation hub and military stronghold during World War II, where the Flying Tigers were stationed in 1942 and conducted missions against Japanese invaders [4]. - The opening ceremony highlighted the historical friendship and mutual sacrifice between the peoples of China and the United States during WWII, emphasizing the significance of this relationship as a testament to solidarity [5][6].

Core Insights - Parsons Corporation has opened a new facility in Redstone Gateway, enhancing its commitment to national security and the defense community in Huntsville [1][2] - The facility spans 27,000 square feet, with 21,000 square feet dedicated to high-bay space for advanced programs, and aims to improve collaboration with government and industry partners [2][3] - This investment aligns with the missions of Redstone Arsenal and the U.S. Department of Defense, emphasizing Parsons' role in delivering next-generation solutions in space and missile defense [3] Company Overview - The new facility is strategically located near Redstone Arsenal, allowing for seamless integration with ongoing defense programs and rapid development cycles [2][3] - Parsons aims to enhance its ability to deliver agile, mission-ready solutions to support the warfighter and national security priorities [2] - The expansion reflects Parsons' ongoing investment in technology, infrastructure, and personnel to meet evolving mission needs in the defense sector [3]